BACKGROUND/AIMS: Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are often increased in patients with impaired renal function. The objective of this study was to investigate whether the increase in NT-proBNP is predominantly due to a reduced renal clearance or an increased cardiac secretion. METHODS: A series of 697 outpatients (age: 57.5 ± 16.4 years) referred for evaluation of dyspnea were assigned to 4 groups according to their estimated glomerular filtration rate [eGFR (ml/min per 1.73 m2)]: group 1, eGFR <60 (n = 77); group 2, eGFR ≧60 to <75 (n = 139); group 3, eGFR ≧75 to <90 (n = 191), and group 4, eGFR ≧90 (n = 289). The patients were also grouped into 2 categories based on the presence (n = 176) or absence (n = 521) of heart disease. RESULTS: In patients with heart disease, the adjusted values for NT-proBNP were higher in eGFR group 1 than in eGFR groups 2-4 (p ≤ 0.01). In patients without heart disease, eGFR group 1 membership had no effect on NT-proBNP. CONCLUSION: A reduced renal clearance does not explain increased NT-proBNP levels in patients with moderate renal impairment and dyspnea. Our data suggest that a moderate reduction in renal function places additional stress on the heart in patients with established cardiac disease.
BACKGROUND/AIMS: Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are often increased in patients with impaired renal function. The objective of this study was to investigate whether the increase in NT-proBNP is predominantly due to a reduced renal clearance or an increased cardiac secretion. METHODS: A series of 697 outpatients (age: 57.5 ± 16.4 years) referred for evaluation of dyspnea were assigned to 4 groups according to their estimated glomerular filtration rate [eGFR (ml/min per 1.73 m2)]: group 1, eGFR <60 (n = 77); group 2, eGFR ≧60 to <75 (n = 139); group 3, eGFR ≧75 to <90 (n = 191), and group 4, eGFR ≧90 (n = 289). The patients were also grouped into 2 categories based on the presence (n = 176) or absence (n = 521) of heart disease. RESULTS: In patients with heart disease, the adjusted values for NT-proBNP were higher in eGFR group 1 than in eGFR groups 2-4 (p ≤ 0.01). In patients without heart disease, eGFR group 1 membership had no effect on NT-proBNP. CONCLUSION: A reduced renal clearance does not explain increased NT-proBNP levels in patients with moderate renal impairment and dyspnea. Our data suggest that a moderate reduction in renal function places additional stress on the heart in patients with established cardiac disease.
Authors: Simon G Williams; Leong L Ng; Russell J O'Brien; Steve Taylor; D Jay Wright; Lip-Bun Tan Journal: Eur J Heart Fail Date: 2004-12 Impact factor: 15.534
Authors: Ronald M A Henry; Piet J Kostense; Griët Bos; Jacqueline M Dekker; Giel Nijpels; Robert J Heine; Lex M Bouter; Coen D A Stehouwer Journal: Kidney Int Date: 2002-10 Impact factor: 10.612
Authors: Alan Maisel; Christian Mueller; Kirkwood Adams; Stefan D Anker; Nadia Aspromonte; John G F Cleland; Alain Cohen-Solal; Ulf Dahlstrom; Anthony DeMaria; Salvatore Di Somma; Gerasimos S Filippatos; Gregg C Fonarow; Patrick Jourdain; Michel Komajda; Peter P Liu; Theresa McDonagh; Kenneth McDonald; Alexandre Mebazaa; Markku S Nieminen; W Frank Peacock; Marco Tubaro; Roberto Valle; Marc Vanderhyden; Clyde W Yancy; Faiez Zannad; Eugene Braunwald Journal: Eur J Heart Fail Date: 2008-08-29 Impact factor: 15.534
Authors: Victoria Cachofeiro; Marian Goicochea; Soledad García de Vinuesa; Pilar Oubiña; Vicente Lahera; José Luño Journal: Kidney Int Suppl Date: 2008-12 Impact factor: 10.545
Authors: Murray J Leikis; Michael J McKenna; Aaron C Petersen; Annette B Kent; Kate T Murphy; James A Leppik; Xiaofei Gong; Lawrence P McMahon Journal: Clin J Am Soc Nephrol Date: 2006-04-19 Impact factor: 8.237
Authors: Marc Vanderheyden; Jozef Bartunek; Gerasimos Filippatos; Marc Goethals; Bruno Van Vlem; Alan Maisel Journal: Congest Heart Fail Date: 2008 Jul-Aug